Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy

被引:150
作者
Grund, Birgit [1 ]
Baker, Jason V. [2 ,3 ]
Deeks, Steven G. [4 ,5 ]
Wolfson, Julian [6 ]
Wentworth, Deborah [6 ]
Cozzi-Lepri, Alessandro [7 ]
Cohen, Calvin J. [8 ]
Phillips, Andrew [7 ]
Lundgren, Jens D. [9 ]
Neaton, James D. [6 ]
机构
[1] Univ Minnesota, Sch Stat, Minneapolis, MN 55455 USA
[2] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
[3] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] San Francisco Gen Hosp, San Francisco, CA 94110 USA
[6] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
[7] UCL, London, England
[8] Gilead Sci Inc, Med Affairs Dept, 353 Lakeside Dr, Foster City, CA 94404 USA
[9] Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark
基金
美国国家卫生研究院;
关键词
CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; INFLAMMATORY MARKERS; REGRESSION DILUTION; RISK; MORTALITY; CANCER; COAGULATION; STROKE; ASSOCIATIONS;
D O I
10.1371/journal.pone.0155100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Despite effective antiretroviral treatment (ART), HIV-positive individuals are at increased risk of serious non-AIDS conditions (cardiovascular, liver and renal disease, and cancers), perhaps due in part to ongoing inflammation and/or coagulation. To estimate the potential risk reduction in serious non-AIDS conditions or death from any cause that might be achieved with treatments that reduce inflammation and/or coagulation, we examined associations of interleukin-6 (IL-6), D-dimer, and high-sensitivity C-reactive protein (hsCRP) levels with serious non-AIDS conditions or death in 3 large cohorts. Methods In HIV-positive adults on suppressive ART, associations of IL-6, D-dimer, and hsCRP levels at study entry with serious non-AIDS conditions or death were studied using Cox regression. Hazard ratios (HR) adjusted for age, gender, study, and regression dilution bias (due to within-person biomarker variability) were used to predict risk reductions in serious non-AIDS conditions or death associated with lower "usual" levels of IL-6 and D-dimer. Results Over 4.9 years of mean follow-up, 260 of the 3766 participants experienced serious non-AIDS conditions or death. IL-6, D-dimer and hsCRP were each individually associated with risk of serious non-AIDS conditions or death, HR = 1.45 (95% CI: 1.30 to 1.63), 1.28 (95% CI: 1.14 to 1.44), and 1.17 (95% CI: 1.09 to 1.26) per 2x higher biomarker levels, respectively. In joint models, IL-6 and D-dimer were independently associated with serious non-AIDS conditions or death, with consistent results across the 3 cohorts and across serious non-AIDS event types. The association of IL-6 and D-dimer with serious non-AIDS conditions or death was graded and persisted throughout follow-up. For 25% lower "usual" IL-6 and D-dimer levels, the joint biomarker model estimates a 37% reduction (95% CI: 28 to 46%) in the risk of serious non-AIDS conditions or death if the relationship is causal. Conclusions Both IL-6 and D-dimer are independently associated with serious non-AIDS conditions or death among HIV-positive adults with suppressed virus. This suggests that treatments that reduce IL-6 and D-dimer levels might substantially decrease morbidity and mortality in patients on suppressive ART. Clinical trials are needed to test this hypothesis.
引用
收藏
页数:16
相关论文
共 44 条
[1]  
Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175
[2]   Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals [J].
Achhra, Amit C. ;
Amin, Janaki ;
Sabin, Caroline ;
Chu, Haitao ;
Dunn, David ;
Kuller, Lewis H. ;
Kovacs, Joseph A. ;
Cooper, David A. ;
Emery, Sean ;
Law, Matthew G. .
AIDS, 2012, 26 (13) :1707-1717
[3]   Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients [J].
Achhra, Amit C. ;
Amin, Janaki ;
Law, Matthew G. ;
Emery, Sean ;
Gerstoft, Jan ;
Gordin, Fred M. ;
Vjecha, Michael J. ;
Neaton, James D. ;
Cooper, David A. .
AIDS, 2010, 24 (12) :1877-1886
[4]   Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer [J].
Allin, Kristine H. ;
Bojesen, Stig E. ;
Nordestgaard, Borge G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2217-2224
[5]   Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection [J].
Baker, Jason V. ;
Neuhaus, Jacqueline ;
Duprez, Daniel ;
Kuller, Lewis H. ;
Tracy, Russell ;
Belloso, Waldo H. ;
De Wit, Stephane ;
Drummond, Fraser ;
Lane, H. Clifford ;
Ledergerber, Bruno ;
Lundgren, Jens ;
Nixon, Daniel E. ;
Paton, Nicholas I. ;
Neaton, James D. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (01) :36-43
[6]   Inflammation, Hemostasis, and the Risk of Kidney Function Decline in the Atherosclerosis Risk in Communities (ARIC) Study [J].
Bash, Lori D. ;
Erlinger, Thomas P. ;
Coresh, Josef ;
Marsh-Manzi, Jane ;
Folsom, Aaron R. ;
Astor, Brad C. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) :596-605
[7]   Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers [J].
Borges, Alvaro H. ;
Silverberg, Michael J. ;
Wentworth, Deborah ;
Grulich, Andrew E. ;
Faetkenheuer, Gerd ;
Mitsuyasu, Ronald ;
Tambussi, Giuseppe ;
Sabin, Caroline A. ;
Neaton, James D. ;
Lundgren, Jens D. .
AIDS, 2013, 27 (09) :1433-1441
[8]   Multimodel inference - understanding AIC and BIC in model selection [J].
Burnham, KP ;
Anderson, DR .
SOCIOLOGICAL METHODS & RESEARCH, 2004, 33 (02) :261-304
[9]   Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy [J].
Butler, Scott L. ;
Valdez, Hernan ;
Westby, Michael ;
Perros, Manos ;
June, Carl H. ;
Jacobson, Jeffrey M. ;
Levy, Yves ;
Cooper, David A. ;
Douek, Daniel ;
Lederman, Michael M. ;
Tebas, Pablo .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (03) :297-303
[10]  
CIOMS Working Group, 2009, INTR GUID STAND MEDD